Authors
Latest:
Open Science and Digital Health: A Brighter Future for Parkinson’s DiseaseCollaborative efforts among researchers, clinicians, and industry are essential to unlock the full potential of digital health in transforming the lives of people with Parkinson's disease.
Latest:
What Makes for a Great Leader in Pharma, and How to Hire OneA look into the traits that hiring managers of pharma companies should be searching for when hiring for a leadership role.
Latest:
Virtual Medical Affairs Audits: A Viable AlternativeVirtual audits proving to be beneficial post-COVID despite continuing challenges.
Latest:
3 Steps to Supercharge Your Rare Disease Advocacy PartnershipsHow these actions can help brand teams form effective and sustainable relationships with patient communities
Latest:
More Than a Trend: Steps to Ensure Patient-Centered Research Stays at the Forefront of PharmaPharma companies are now under increasing pressure, and increasingly willing, to offer a patient-centric approach. But with this increasing demand comes confusion about what patient-centered research actually is.
Latest:
The Architecture of Global, Scalable, Next-Generation Patient Support ProgramsPatient support programs (PSPs) have an opportunity for growth and innovation.
Latest:
Tapping NPs and PAs in Life Sciences MarketingAmid the shifting focus from primary care to specialty care, using data-driven tactics can create tailored campaigns and meaningful relationships with nurse practitioners and physician assistants.
Latest:
The Shifting Landscape of the Life Sciences Job MarketPlanning for a post-recession scenario is essential, ensuring companies are prepared to scale up when funding permits.
Latest:
Why Program Management is the Key to Success for Life Science CompaniesDelivering value with enterprise program management.
Latest:
From Clinical Trials to Market Success: 3 Approaches You Can Use Right Now for Allogeneic TherapiesPatient centricity and access highlight keys to success for new development.
Latest:
The Intelligent AI ConsumerArtificial Intelligence (AI) fueled by real-world healthcare data has yet to be fully leveraged by biopharmaceutical companies but is poised to revolutionize their business strategies.
Latest:
Ecolab Continues Mission to Protect What's Vital With Deep Investment in Life SciencesEcolab is looking to the future with new opportunities to partner with Pharma for critical solutions to support drug development and manufacturing.
Latest:
PREP Act Protections for COVID-19 Vaccine LiabilityHow PREP Act protections will apply to potential COVID-19 vaccine-related claims.
Latest:
Best Practices for Balancing Medical Affairs Globalization with Local RequirementsAddressing the challenges faced by Global Medical Affairs teams and how they can find balance to create maximum value for their organizations.
Latest:
The IRA Impact: Navigating Its Evolving ComplexitiesAmid lingering questions and uncertainty, a look at ways pharma companies can prioritize incorporating the Inflation Reduction Act into their strategic planning process—and do it now.
Latest:
China’s 2022 NRDL ReadoutDespite the twists and turns, 2022 turned out to be a banner year for National Reimbursement Drug List’s new inclusions—and with welcomed upgrades to bidding and renewal rules.
Latest:
The Quest to Fully Address Prescription Drug AffordabilityThe Medicare Part D cap won’t solve need for financial assistance.
Latest:
The JAKs Journey Offers Valuable Lessons for InnovatorsOpportunity remains despite regulatory and access obstacles.
Latest:
Why A New Mix of Field Skills is Crucial to Thriving in the Digital EraEvolving preferences of HCPs during the pandemic have put an emphasis on learning new skillsets for pharma reps.
Latest:
SPBMs: Impact on Accessibility & Affordability of Gene Therapies for Rare and Orphan DiseasesThe introduction of alternative payment models and specialty pharmacy benefit management (SPBM) is poised to usher in a new era of affordability for expensive gene therapies.
Latest:
The Department of Justice is Watching: Building a Data-Driven Compliance ProgramWhether your company already has a data-driven compliance program in place or is contemplating building one, Michael O'Connor and Isha Arora outline four things the DOJ is now focused on that your compliance team needs to know.
Latest:
When to Utilize Commercial OutsourcingWhen deciding on the right commercialization model, organizations must consider multiple factors, including the asset or platform they possess, the launch timing, the funding required, and staffing expertise.
Latest:
Investing for Success: Finding the Right Launch BalanceChallenge assumptions and reset expectations when it comes to pre-launch SG&A investment to increase the odds of commercial success.
Latest:
A Case for Payer Engagement and Participation in Clinical ResearchCollaboration can make commercialization processes efficient and effective.
Latest:
The Teladoc-Livongo Merger: Life Science Manufacturers’ Darwinian MomentThe recent merger of Teledoc and Livongo into a $38 billion titan proves that the market sees opportunity in health tech. Could it be an inflection point in our race towards a digital-first care model, or is this an experiment ahead of its time?
Latest:
How Medical Affairs Can Contribute to Successful Drug LaunchFaster launch planning leads to greater access.
Latest:
China: The Giant Has AwokenWith a new Chinese pharma or biotech company listing on either the HKEX or STAR exchange in China almost every week, it is important consideration US pharma and biotech companies to have a focused China market strategy, writes Enoch Kariuki.
